Stryker (SYK) Cash from Financing Activities (2009 - 2026)
Stryker's (SYK) quarterly Cash from Financing Activities came in at -$1.5 billion in Q1 2026, down 159.59% year-on-year from $2.5 billion in Q1 2025, and down 38.15% on a QoQ basis from -$1.1 billion in Q4 2025.
Stryker (SYK) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Stryker (SYK) has 18 years of Cash from Financing Activities data on file, last reported at -$1.5 billion in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 159.59% year-over-year to -$1.5 billion in Q1 2026; TTM through Mar 2026 was -$3.9 billion, a 261.97% decrease from a year earlier, with the FY2025 full-year figure at $113.0 million, up 121.52% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$1.5 billion, down from -$1.1 billion in the prior quarter.
- Over the last five years, Cash from Financing Activities for SYK reached as high as $2.7 billion in Q3 2024 and fell as low as -$1.8 billion in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$250.9 million across 5 years, with a median of -$446.0 million in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 728.67% in 2024 and fell as far as 527.27% in 2024.
- Year by year, Cash from Financing Activities stood at -$446.0 million in 2022, then soared by 35.87% to -$286.0 million in 2023, then slumped by 527.27% to -$1.8 billion in 2024, then soared by 39.07% to -$1.1 billion in 2025, then plunged by 38.15% to -$1.5 billion in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$1.5 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$339.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Steris | 20.59 Bn | 20.16 Bn | 697.10 Mn | -97.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.51 Bn |
| Mar 31, 2026 | -1.51 Bn |
| Dec 31, 2025 | -1.09 Bn |
| Dec 31, 2025 | -1.09 Bn |
| Sep 30, 2025 | -339.00 Mn |
| Sep 30, 2025 | -339.00 Mn |
| Jun 30, 2025 | -989.00 Mn |
| Jun 30, 2025 | -989.00 Mn |
| Mar 31, 2025 | 2.53 Bn |
| Mar 31, 2025 | 2.53 Bn |
| Dec 31, 2024 | -1.79 Bn |
| Dec 31, 2024 | -1.79 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Sep 30, 2024 | 2.65 Bn |
| Jun 30, 2024 | -966.00 Mn |
| Jun 30, 2024 | -966.00 Mn |
| Mar 31, 2024 | -418.00 Mn |
| Mar 31, 2024 | -418.00 Mn |
| Dec 31, 2023 | -286.00 Mn |
| Dec 31, 2023 | -286.00 Mn |